Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 4/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741304 | 0.82 | MMP1 (0.31) | MMP2MMP3 | |
| SCHEMBL741483 | 0.79 | — | — | |
| SCHEMBL741875 | 0.78 | — | — | |
| SCHEMBL4957807 | 0.77 | HRH1 (0.47) | HRH1LOXL2HRH4HRH3RAB9A | |
| SCHEMBL2027168 | 0.76 | LOXL2 (0.41) | HRH1LOXL2HRH3RAB9AALDH1A1 | |
| SCHEMBL581041 | 0.72 | LOXL2 (0.37) | LOXL2RAB9AALDH1A1 | |
| SCHEMBL13018522 | 0.72 | HRH1 (0.47) | HRH1LOXL2HRH4HRH3RAB9A | |
| SCHEMBL14453298 | 0.71 | SIGMAR1 (0.34) | — | |
| SCHEMBL1516258 | 0.69 | DPP4 (0.37) | — | |
| SCHEMBL11972243 | 0.69 | ADRB2 (0.38) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2431365-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP2C9, QDPR | HRH1 394/4885LOXL2 2787/4885HRH4 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.